XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.2

Segment, Geographical and Other Revenue Information (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

			Three Months Ended June 30, 2023																		Three Months Ended June 30, 2022
			Performance Enzymes						Novel Biotherapeutics						Total						Performance Enzymes						Novel Biotherapeutics						Total
Revenues:
Product revenue			$	11,048					$	—					$	11,048					$	34,645					$	—					$	34,645
Research and development revenue			8,260						2,015						10,275						1,885						1,876						3,761
Total revenues			19,308						2,015						21,323						36,530						1,876						38,406
Costs and operating expenses:
Cost of product revenue			3,178						—						3,178						11,270						—						11,270
Research and development (1)			7,856						8,240						16,096						6,929						11,078						18,007
Selling, general and administrative (1)			2,032						191						2,223						3,876						680						4,556
Restructuring charges			—						72						72						—						—						—
Total segment costs and operating expenses			13,066						8,503						21,569						22,075						11,758						33,833
Income (loss) from operations			$	6,242					$	(6,488)					(246)						$	14,455					$	(9,882)					4,573
Corporate costs (2)															(9,788)																		(5,789)
Unallocated depreciation and amortization															(1,480)																		(1,316)
Loss before income taxes															$	(11,514)																	$	(2,532)

			Six Months Ended June 30, 2023																		Six Months Ended June 30, 2022
			Performance Enzymes						Novel Biotherapeutics						Total						Performance Enzymes						Novel Biotherapeutics						Total
Revenues:
Product revenue			$	19,412					$	—					$	19,412					$	65,335					$	—					$	65,335
Research and development revenue			9,382						5,511						14,893						4,294						4,117						8,411
Total revenues			28,794						5,511						34,305						69,629						4,117						73,746
Costs and operating expenses:
Cost of product revenue			7,698						—						7,698						19,791						—						19,791
Research and development (1)			15,955						15,552						31,507						13,051						23,424						36,475
Selling, general and administrative (1)			4,830						1,142						5,972						7,416						1,400						8,816
Restructuring charges			—						145						145						—						—						—
Total segment costs and operating expenses			28,483						16,839						45,322						40,258						24,824						65,082
Income (loss) from operations			$	311					$	(11,328)					(11,017)						$	29,371					$	(20,707)					8,664
Corporate costs (2)															(20,152)																		(16,994)
Unallocated depreciation and amortization															(2,946)																		(2,549)
Loss before income taxes															$	(34,115)																	$	(10,879)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other expense, net.

The following table provides stock-based compensation expense included in loss from operations (in thousands):

			Three Months Ended June 30,
			2023																								2022
			Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total						Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total
Stock-based compensation			$	924					$	(80)					$	1,872					$	2,716					$	1,493					$	358					$	1,380					$	3,231

			Six Months Ended June 30,
			2023																								2022
			Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total						Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total
Stock-based compensation			$	1,959					$	333					$	3,233					$	5,525					$	3,183					$	768					$	3,118					$	7,069

Schedule of Customers that Contributed 10% or More of Total Accounts Receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:

			Percentage of Total Revenues for the
			Three Months Ended June 30,												Six Months Ended June 30,
			2023						2022						2023						2022
Customer A			28		%				62		%				17		%				62		%
Customer B			18		%				*						11		%				*
Customer C			11		%				*						*						*
Customer D			*						*						11		%				*
Customer E			*						*						10		%				*
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:

			Percentage of Accounts Receivables as of
			June 30, 2023						December 31, 2022
Customer A			*						53		%
Customer D			11		%				*
Customer E			12		%				10		%
Customer F			17		%				*
Customer G			14		%				*
Customer H			12		%				*
* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

			Three Months Ended June 30,												Six Months Ended June 30,
			2023						2022						2023						2022
Revenues
Americas			$	3,937					$	3,614					$	6,521					$	7,347
EMEA			8,349						4,690						11,438						8,817
APAC			9,037						30,102						16,346						57,582
Total revenues			$	21,323					$	38,406					$	34,305					$	73,746

Schedule of Long-Lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):

			June 30, 2023						December 31, 2022
United States			$	60,070					$	61,877

Schedule of Intangible Assets and Goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):

			As of June 30, 2023 and December 31, 2022
			Performance Enzymes						Novel Biotherapeutics						Total
Goodwill			$	2,463					$	778					$	3,241

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

+ Details

Name:	us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration